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ABSTRACT
Background: In 2002, the National Institute for Health and
Clinical Excellence (NICE), recommended atypical antipsy-
chotics over conventional ones for ﬁrst-line schizophrenia
treatment, based on their lower risk of extrapyramidal
symptoms.
Objective: To estimate the incremental cost-effectiveness of
atypical relative to conventional antipsychotics for the treat-
ment of schizophrenia in the UK.
Methods: A discrete event simulation (DES) model was
adopted to reﬂect the treatment of schizophrenia in the UK.
The model estimates symptoms (using the Positive and Nega-
tive Symptom Score [PANSS]), psychiatrist visits, pharmaco-
logical treatment and treatment location, number and
duration of psychotic relapses, level of compliance, quality-
adjusted life-years (QALYs), and side effects over a 5-year
time period. Probabilistic sensitivity analyses were carried
out. Following NICE’s “atypical” recommendation, the cost-
effectiveness of atypical versus conventional antipsychotics
was estimated in a scenario analysis, assuming both groups
differ only in side-effect proﬁle.
Results: When comparing conventional and atypical antip-
sychotics, the model predicts that the latter would decrease
5-year costs by £1633 per patient and result in a QALY gain
of 0.101. The probabilistic sensitivity analysis suggests these
results are robust. The sensitivity analyses indicate that incre-
mental costs and effects are most sensitive to the differential
efﬁcacy of atypicals and conventionals, as measured by
PANSS. When it is assumed that the only differences between
atypicals and conventionals are found in side-effect proﬁles,
the incremental cost-effectiveness ratio of the atypicals is
£45,000 per QALY gained.
Conclusion: According to this DES model for schizophrenia,
atypical antipsychotics are cost-effective compared to the
conventional antipsychotics. The assumptions used in the
model need further validation through large naturalistic
based studies with reasonable follow-up to determine the
real-life differences between atypicals and conventional
antipsychotics.
Keywords: cost-effectiveness analysis, discrete event simula-
tion, modeling, probabilistic multivariate sensitivity analyses,
schizophrenia, UK.
Introduction
Schizophrenia is a chronic disease with no deﬁnitive
cure. The prevalence of the condition is estimated at
between 0.2% and 1% in the general population [1,2].
Schizophrenia typically starts at a young age with con-
siderable impact on the patients and their social
system. As a result, the societal costs of schizophrenia
are substantial. According to Mangalore and Knapp,
the estimated total societal cost of schizophrenia in the
UK was 6.7 billion pounds in 2004 to 2005 [3].
The National Institute for Health and Clinical
Excellence (NICE) recommends that atypical antipsy-
chotics should be considered ﬁrst-line treatment for
newly diagnosed schizophrenia patients, particularly
when full discussion between clinician and patient is
not possible [1,4]. This recommendation is based on
the lower potential risk of extrapyramidal symptoms
(EPS) on atypical antipsychotics than on conventional
ones. The guidance recognizes that patients who are
currently successfully treated with a conventional need
not be switched to an atypical antipsychotic when
symptom control is adequate and side effects are
acceptable. The present study addresses the cost-
effectiveness of the use of atypical antipsychotics in the
early treatment of schizophrenia.
Reliable data of the long-term impact of schizophre-
nia and its treatment are scarce, both in terms of
clinical as well as economic outcomes. Additionally
such data are often of poor quality and difﬁcult to
generalize among a broad population [5]. This
hampers making well-informed decisions concerning
reimbursement and treatment guidelines. A health eco-
nomic model, which consolidates the available evi-
dence in a structured manner, may, however, be able to
help gain insight into the different mechanisms which
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inﬂuence treatment outcomes. While the outcomes of
such a model should be treated with caution [5], they
can still be of great value in serving as a starting point
for further research and discussion. It may be argued
that the lower the quality of the evidence is, the more
closely a model should reﬂect clinical practice and rely
on explicit assumptions and interdependencies, so that
the impact of each can be individually tested and
reviewed. Furthermore, this approach potentially
makes the model more suitable for the inclusion of
expert opinion to complement the published literature,
as the level of abstraction is reduced to a minimum.
This realization, along with the highly heterogeneous
and time-dependent nature of the illness and its pro-
gression, makes schizophrenia a highly suitable candi-
date for discrete event simulation (DES) [6,7]. DES
models allow for the simulation of individual patients
and they are highly ﬂexible in terms of their time
frame, as well as the inclusion of a large number of
interdependencies with respect to individual patient
characteristics and their treatment histories.
The current article aims to provide insight and
understanding regarding the clinical and economic
effects of the treatment of schizophrenia, using a
nonproduct-speciﬁc DES model which represents the
use of pharmacological agents in day-to-day clinical
practice in the UK. The objective was to assess the
cost-utility of atypical versus conventional antipsy-
chotics based on their respective market shares in the
UK treatment setting.
Methods
Perspective
The analysis of costs is restricted to health and social
care costs borne by the NHS and social care trusts.
Hence only the direct costs of medication, psychiatric
visits, and costs associated with residing in speciﬁc
treatment locations (e.g., community treatment,
staffed hostel, or hospital) are included. In accordance
with NICE guidelines, costs and effects are discounted
at a rate of 3.5% [8]. Indirect costs are not included in
the analysis because little research has been carried out
on the impact of antipsychotic treatment on indirect
costs and it is unclear whether differences in indirect
costs between different treatments are to be expected.
In any case, indirect costs are not expected to be higher
on atypicals than on conventionals [9,10].
Data Sources and Discrete Event Model
Previous versions of the DES model used for this analy-
sis have been described in detail elsewhere [11–13].
Where possible, parameter estimates were updated
based on published literature or with information from
secondary database analyses (from the ongoing Uni-
versity Medical Center Utrecht database of schizophre-
nia patients). The DES model was programmed using
Extend software (Imagine That Inc., San Jose, CA).
The model describes the course of treated schizophre-
nia over 5 years. Schizophrenia is a chronic disease and
therefore theoretically a lifetime time horizon should
be considered when modeling schizophrenia. Never-
theless, because of the lack of long-term data on the
course of schizophrenia, a 5-year time horizon was
chosen. This time horizon is sufﬁcient to capture the
relevant health and economic consequences of the
treatments under comparison, because patients typi-
cally switch quite frequently between antipsychotics
[14], and both treatment arms have the same second-,
third-, and fourth-line treatment.
Comparisons Made
The treatment strategies that are compared using this
DES model are outlined in Figure 1. When the patient
enters the model or switches treatment, an antipsy-
chotic is selected based on UK market share data (IMS
November 2005) [15] in order to approximate treat-
ment selection in clinical practice. Little data are avail-
able about the distribution of the different drugs at
different stages of treatment, so it is assumed that this
distribution is the same throughout. The choice of
second, third, and fourth treatment has little impact on
incremental results because these distributions are the
same in both treatment arms. Up to three treatment
switches are allowed in the 5-year model (Fig. 1). Fol-
lowing expert opinion and the NICE treatment guide-
lines, all patients switch to clozapine after the third
treatment [16].
Model Structure
The development of the current DES model was initi-
ated in 2000. Initially, model inputs were, to a large
extent, based on expert opinion. Nevertheless, over
time the model was increasingly populated (and vali-
dated) using published data or secondary database
analysis. Previous versions of the DES model used for
this analysis have been described in detail elsewhere
[11–13]. Structural changes to the model incorporate
the possibility for probabilistic sensitivity analyses, as
well as additional outcome measures, partial compli-
ance, and three instead of two treatment switches.
Patients enter the model while suffering an episode
for which the care of a psychiatrist is sought. It is
assumed the patient is presenting early on in the course
of the illness, but it is not the ﬁrst episode of psychosis
(as distinct from ﬁrst episode of schizophrenia),
because the diagnosis of chronic schizophrenia cannot
be made based on a single psychosis. Therefore,
patients may not be treatment naïve. Figure 2 provides
a graphical representation of a hypothetical patient
history. During each visit, the next visit is planned and
the patient’s location of care, treatment, and compli-
ance are re-evaluated. The variables included in the
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model are either ﬁxed (patient characteristics/
attributes) or time dependent.
Fixed Patient Attributes
Simulation of individual patient histories starts with
selecting a number of attributes from a set of prespeci-
ﬁed probability distributions:
1. Patient proﬁle (which determines whether a
patient recovers fully or partially between relapses
in terms of the symptom score—38% of patients
recover fully, 62% partially) [17];
2. The severity of illness of the patient (mild 10%,
medium 80%, or severe 10%) [11];
3. Social and environmental factors (SEF: a random
score between 0 and 100 which represents a
patient’s informal care network (as previously
described [11]); and
4. Whether a patient will suffer from side effects
when put on a speciﬁc medication (see Table 1).
Once the time-independent attributes are assigned
to a patient, the model simulates disease progres-
sion based on a number of interdependent time-
dependent variables.
Side-effect incidence rates were calculated by multiply-
ing the incidence of the relevant side effects on olanza-
pine (for EPS [18], tardive dyskinesia [19], somnolence
[20], weight gain [>7%of initial body weight], [21] and
diabetes [22]) by the relative risk reported in the
Cochrane reviews of the various antipsychotics
[23–34]. This approachwas taken because little directly
comparative data are available. By anchoring side
effects for the other treatments on olanzapine data and
using relative risks, some of the differences in trial
design (such as dosing, length of trial, etc.), whichmake
it difﬁcult to use the raw data on which these relative
risks were based, become less relevant.
Time-Dependent Variables
After these ﬁxed attributes are assigned to a patient,
the model simulates disease progression based on a
number of interacting time-dependent variables. The
two major time-dependent variables are the patient’s
health state at a certain moment (whether the patient is
in relapse or is in between relapses) and the result of
reassessment of medication and treatment location
during psychiatrist visits. A patient’s health state inﬂu-
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Figure 1 Overview of modeled pharmaceutical treatment strategies and the treatments probabilities in the ﬁrst, second, third, and fourth treatment after
model entry, based on UK market shares [15].
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ences the PANSS score which is associated with
changes in quality-adjusted life-years (QALYs) [35].
Other time-dependent variables such as the level of
compliance (fully, partially, or noncompliant), the risk
to harm self and/or others, and the ability of a patient
to care for him- or herself are dependent on a patient’s
PANSS score. The treatment characteristics (i.e., treat-
ment and location) are determined during the psychi-
atric visits, based on the various interdependencies
between the time-dependent and time-independent
variables. In the following section, these interdepen-
dencies will be brieﬂy elaborated upon.
Psychiatric Visits
Upon model entry, the simulated patient visits a psy-
chiatrist. During each visit to the psychiatrist, the
choice of treatment location and medication is evalu-
ated. Psychiatrist visits in the model are scheduled
more frequently after a treatment switch or hospital-
ization (when the frequency is once a month), and less
frequently in times when a patient is stable when the
frequency is one visit every 6 months.
Medication
The decision to switch to another medication regime
depends on whether or not the patient is in relapse
while on the current medication. Nevertheless, even if
the patients do not suffer from a relapse, a medication
change can be prescribed because of the occurrence of
a side effect [4]. The probabilities which are being used
to determine the medication to which a patient is
transferred are speciﬁed in Table 1, be it that patients
will not be prescribed the same medication twice.
Treatment Location
In clinical practice, patients can be treated in a wide
variety of settings. For modeling purposes, this was
simpliﬁed down to four treatment settings: regular or
intensive community care (with one nurse visit every
fortnight or two nurse visits every week, respectively),
in a staffed hostel (group living accommodations with
some staff on site), or in a hospital. These locations
were selected based on expert opinion to capture the
main locations where the majority of patients with
schizophrenia can be found. The treatment location
decision depends on whether the patient presents an
actual risk to him/herself or to society and whether the
patient can take care of him/herself. The probability of
presenting a risk was based on a logistic regression
analysis specifying the association between risk to self
and others, and PANSS in long-term cohort data from
the University Medical Center Utrecht, The Nether-
lands, using a logistic regression model [36]. Addition-
ally, because experts indicated that symptoms were not
the only driver, another random score was included,
called social and environmental factor (SEF), reﬂecting
all other factors inﬂuencing the patients’ location deci-
sion that are not linked to symptoms, such as whether
patient lives at home, has a job, etc. In the model,
patients with a high PANSS and/or a high SEF score
are assumed to have difﬁculties taking care of them-
selves modeled using the disability to care index (DCI).
Time
Time-dependent Variables
shtnom111111
Time-independent variables
ecnailpmoCredneG )a( seY  seY  
(b) Age         No
(e) Patient Type
  Yes
  No   No
  Home
  Hospital
QALY, SF6, PSP
Episodes
Psychiatrist Visits
Treatment
PANSS
Risk to self/others
 3rd line
3
Treatment setting
  1st line
  2nd line
2 6
Disability to take
care of oneself
(c) Side-effect
(d) Severity
(e) Social Environmental 
Factors
2
Figure 2 Example of patient history from time of entering model during relapse at visit to psychiatrist. QALY, quality-adjusted life-year; PSP, personal and
social performance scale; SF6, short form 6 mental health component; PANSS, Positive and Negative Symptom Score.
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The latter variable depends on PANSS, SEF, and alpha
weight. The alpha weight represents the weight of
PANSS in the DCI. If the weight of PANSS in the DCI
is high, the difference in PANSS reduction between
conventionals and atypicals will have a stronger
impact on the hospitalization decision (see Appendix
A) [11]. If the patient presents a risk or is unable to
care for himself, the probability of going to (or staying
at) the more intensive care settings (like hospital) is
high. If the opposite applies, patients may be sent
home, or to a less intensive care setting (like a staffed
hostel). The transition probabilities are presented in
Table 1. For instance, a patient who cannot take care
of him/herself and is located in a hospital has a 63%
chance to remain in the hospital. The latter is not
100% because experts indicated that availability of
services is limited. The average duration of hospital-
ization for schizophrenia (ICD code F20) is 40 days,
based on hospital episode statistics from the Depart-
ment of Health [37].
Table 1 Overview quantiﬁed model parameters
Probability of side effects
EPS (%)
[18]
Tardive dyskinesia
(%) [19]
Sedation/Somnolence
(%) [20]
Weight gain (%)
[21]
Diabetes (%)
[22]
Agranulocytosis
(%) [83]
Low-potency conventionals
(chlorpromazine,
sulpiride) [23,24]
32.70 3.50 48.90 10.00 0.50 0.00
High-potency conventionals
(others) [25,26]
58.00 5.40 48.90 10.00 0.50 0.00
Aripiprazole [27] 23.90 0.80 26.20 20.50 0.60 0.00
Amisulpride [28] 32.70 1.50 27.30 13.50 0.50 0.00
Risperidone [29] 27.30 0.70 27.30 19.30 0.50 0.00
Olanzapine [31] 15.50 0.50 29.70 41.00 1.00 0.00
Quetiapine [32] 19.90 0.70 55.50 32.50 0.90 0.00
Clozapine [33,34] 14.60 0.00 45.30 57.80 1.60 1.00
Probability to switch treatment
because of side effect
70 90 35 50 90 100 Exp. Op.
Compliance probabilities
between relapses
Conventional
oral
Conventional
depot
Oral atypical
agents
Long-acting
risperidone
Exp. op.
[52–58]
Community treatment 0.600 0.80 0.650 0.850
Intense community treatment 0.750 0.95 0.800 0.990
Sheltered living 0.650 0.85 0.700 0.900
Hospital/Institute 0.800 0.95 0.850 0.990
Patients who present risk from:
To:
Community
care
Intense
community care
Sheltered
living Hospital Exp op.
Probabilities to switch care setting
Community treatment 0.05 0.00 0.00 0.00
Intense community treatment 0.15 0.20 0.20 0.00
Sheltered living 0.00 0.00 0.10 0.00
Hospital 0.80 0.80 0.70 1.00
Patients who can take care of
themselves well/moderately/not
Expert opinion
Community treatment 0.98/0.70/0.10 0.90/0.05/0.00 0.30/0.05/0.00 0.80/0.75/0.05
Intense community treatment 0.02/0.10/0.10 0.10/0.85/0.50 0.00/0.00/0.00 0.10/0.10/0.20
Sheltered living 0.00/0.10/0.10 0.00/0.00/0.00 0.70/0.90/0.15 0.10/0.15/0.12
Hospital 0.00/0.10/0.60 0.00/0.10/0.50 0.00/0.05/0.85 0.00/0.00/0.63
Total recovery
(partial recovery)
Nonsevere
patients
Medium-severe
patients
Very severe
patients
Positive and Negative Symptom
Score (PANSS) and duration of
(time between) relapses per
patient proﬁle (partial recovery
patients in brackets)
PANSS relapse No treatment 68 (77) 94 (81) 111 (86) [26,46,70]
Conventional drugs 60 (68) 83 (72) 99 (77)
Atypical drugs 56 (64) 78 (67) 92 (71)
PANSS between relapses No treatment 52 (49) 52 (52) 52 (56) [26,46,70]
Conventional drugs 52 (40) 52 (43) 52 (47)
Atypical drugs 49 (36) 49 (38) 49 (41)
Time between relapses (months) Conventional drugs 20.2 (17.2) 18.4 (15.6) 16.5 (14.0) [26,39,42,44]
Atypical drugs 22.5 (19.2) 20.5 (17.4) 18.4 (15.7)
Partially noncompliant 10.1 (8.6) 9.2 (7.8) 8.3 (7.0)
Noncompliant 6.1 (5.2) 5.5 (4.7) 5.0 (4.2))
Duration of relapse full
(partial) recovery (in years)
0.18 (0.9) 0.46 (1.0) 0.66 (1.12) Exp. Op.
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Relapse and PANSS
A patient history starts while the patient is in relapse.
The duration of a relapse is drawn randomly from a
predeﬁned duration distribution that depends on
patient proﬁle and severity. Time between relapses is
drawn from another distribution, and depends on
patient proﬁle, severity, current treatment, and
compliance [17,26,38–44]. The model keeps track of
patients’ PANSS scores, ranging from 30 (least severe)
to 210 (most severe) [45]. During a relapse, the PANSS
score is higher than between relapses. PANSS scores
can decrease through natural recovery or by means of
pharmacological treatment.
For total recovery patients, the PANSS score will
drop to the same level after a relapse. For partial
recovery patients, the between-relapse PANSS score
will increase after each relapse [43]. The model ﬁrst
calculates a “base” PANSS score as if the patient is
noncompliant, after which the PANSS is corrected for
the treatment effect of the speciﬁc drug the patient is
on. During relapses, atypicals are assumed to reduce
base PANSS by 20% and conventionals by 10%. Such
a difference between conventionals and atypicals was
substantiated by several studies and meta-analyses
[5,46–51]. Between relapses, atypicals were assumed
to reduce PANSS by 5%, whereas conventionals were
assumed not to reduce PANSS throughout this period
[26].
Compliance
The treatment effect is mitigated by compliance, which
in turn depends on treatment location and drug
regimen. Patients are assumed to be more compliant in
hospital than at home [52,53], while patients on a
depot are assumed to be more compliant than patients
on oral formulation [54–56]. Moreover, patients are
assumed to be slightly more compliant on an atypical
than on a conventional antipsychotic (see Table 1)
[52,57,58]. Finally, based on expert opinion, it was
assumed that patients are 5% less compliant during
relapse than between relapses.
The model ﬁrst determines whether a patient is
compliant or not, based on the aforementioned vari-
ables. If a patient is noncompliant, the model subse-
quently determines whether the patient is compliant
(totally noncompliant, 60%) or partially noncompli-
ant 40% during that period [58]. The impact of treat-
ment in partially noncompliant patients in terms of
PANSS reduction is put at 50% and the effect on time
between relapses is halved as well. The impact of treat-
ment in fully noncompliant patients is zero.
Quality of Life
A patient’s quality of life (i.e., utility index) is derived
from his/her PANSS score and the presence of side
effects. The association between PANSS and utility is
estimated on the basis of the relation found by Lenert
et al. [35]. To estimate the impact of the different side
effects, a multiplicative model is being used, where the
parameters associatedwith weights gain are 0.959 [35],
with tardive dyskinesia 0.857 [35], with diabetes 0.81
[59,60], with EPS 0.888 [35], and with sedation/
somnolence 0.905 [61]. EPS and sedation/somnolence
are assumed to exist as long as the medication is pre-
scribed which caused it. Weight gain, tardive dyskine-
sia, and diabetes were assumed to last for the remainder
of the time that the patient was included in the model,
based on the more enduring nature of these side effects.
Costs
The annual cost per medication is calculated using
data from the British National Formulary [62] and the
Deﬁned Daily Dosages, as reported by the WHO (see
Table 2) [62]. The costs of the different care settings
were retrieved from the Unit Costs of Health and
Social Care Report 2006 (£96 psychiatrist visit [per
patient contact of half an hour], £56 per fortnight for
community care, £112 per week for intensive commu-
nity care, £443 per week for a staffed hostel for
patients with mental health problems, and £181 per
day for psychiatric hospital care) [63].
The main outputs of the model are the predicted
incremental discounted costs (expressed in £ per
patient) and effects (expressed in QALYs per patient)
after 5 years for atypicals compared to conventionals.
Using these differences in cost and effect, the incremen-
tal cost-utility ratio (ICUR) of the atypicals was calcu-
lated (expressed as the cost per QALY gained). Besides
QALYs, the effect outcomes also include information
concerning symptoms, the number and duration of
Table 2 Overview of considered antipsychotics, their dose, and the corresponding acquisition costs
Atypicals
Daily
dose (mg)
Annual
costs Conventionals Daily dose (mg)
Annual
costs
Amisulpride 400 £747 Chlorpromazine 300 £169
Aripiprazole 15 £1325 Haloperidol oral 8 £93
Clozapine 300 £964 Flupentixol decanoate 120 (per month) £196
Olanzapine 10 £1036 Sulpiride 800 £263
Quetiapine 400 £1379 Triﬂuoperazine 20 £69
Oral risperidone 5 £1024 Zuclopenthixol depot 450 (per fortnight) £175
Long-acting risperidone 25 (per fortnight) £2162
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relapses, and the amount of time spent in different
treatment locations or on different treatments.
The inﬂuence of the uncertainty surrounding
parameter estimates (i.e., second-order uncertainty) on
the results is assessed using a probabilistic multivariate
sensitivity analysis (or Monte Carlo simulation) and
several deterministic univariate sensitivity analyses.
Pert, beta, lognormal, and uniform distributions
were used to describe the second-order uncertainty of
relevant variables (Table 3). Different distributions
were used for different variables based on variable
characteristics [64]. For the variables for which the
level of uncertainty was unknown, uniform or Pert
distributions were used. Such distributions allow for
the speciﬁcation of a ﬁxed minimum, maximum, and
most likely value [64].
Based on the costs and effects generated from 1000
cohorts of 10,000 patients, a cost-effectiveness scatter
plot and acceptability curves were constructed [65].
The scatter plot is an illustration of the uncertainty
surrounding the central estimate of the ICUR. Accept-
ability curves summarize the uncertainty associated
with the decision to adopt a new treatment strategy for
different willingness-to-pay (WTP) thresholds per
QALY gained.
In order to investigate the effect of individual
parameters on the outcomes generated in the pro-
babilistic sensitivity analysis (incremental QALYs and
incremental costs), an ordinary least squares (OLS)
regression analysis was performed. This regression is
performed using the inputs and incremental costs and
effects from all 1000 cohorts.
Table 3 Overview of included uncertainty of model input parameters
Variable Base case Distribution Parameters
Time between relapses [70] Weibull beta atypicals Normal SE = 1.75
Weibull beta conventionals (see Table 1) Normal SE = 1.72
PANSS See Table 1 for different patient groups Pert* Min = +10%
Max = -10%
Difference in PANSS reduction
atypicals vs. conventionals
During relapse 10% in favor of atypicals Pert* Min = -0.05
Max = 0.25
ML = 0.10
In between relapses 5% in favor of atypicals Pert* Min = -0.05
Max = 0.15
ML = 0.05
QALY [35] b0 = 1.103 Normal* SE = 0.11
b1 = -0.0043 SE = 0.00043
Risk† b0 = -5.13 Normal SE = 1.22
b1 = 0.0403 SE = 0.016
Patient proﬁle [17] Share of partial recovery patients (0.62) Beta* Alpha = 52
Severity Percentage medium severe = 80% Pert* Beta = 32
Min = 70%
Max = 90%
ML = 80%
Duration hospitalization Mean = 40 Normal* SE = 3.4
Switching care setting probabilities Probability hospitalization (Table 1) Uniform* Min = -15%
Max = +15%
Side-effect probabilities Base-case probabilities (Table 1) Normal‡ SD = 25% of
base-case estimate
Utility weight side effects [35,59,61] Weight gain: 0.959 Normal SD = 0.0102
TD: 0.857 SD = 0.0163
EPS: 0.888 SD = 0.0168
Sedation: 0.905 SD = 0.0184
Diabetes: 0.81 SD = 0.0133*
Probabilities to switch treatment
because of side effects
Base-case probabilities (Table 1) were multiplied by: Uniform* Min = 0.9
Max = 1.1
Shortened time between
episodes because of noncompliance
3.3 for conventionals Pert* Min = -10%
3.7 for atypicals Max = +10%
ML = 3.32/3.7
Care setting costs [84] See section 0 Lognormal* SE = 10%
Difference compliance atypicals
and conventionals
5% in favor of atypicals Pert* Min = 0%
Max = 10%
ML = 5%
Probability partial compliance [38] If noncompliant: 40% partially noncompliant Pert* Min = 0%
Max = 100%
ML = 40%
Alpha weight (a) for PANSS in DCI 0.5 Uniform* Min = 0.4
Max = 0.6
*For the distributions marked with an asterisk, the shape and interval of the uncertainty distribution were not available in the literature and are assumed, based on parameter
characteristics and the level of uncertainty that existed among the experts.
†From B.M.S. Heeg, unpubl. ms.
‡For the side-effect incidence rates, not all conﬁdence intervals were available. For all side effects, a normal distribution with a large SE of one-sixth (16.7%) of the base-case
estimate was assumed.
DCI, disability to care index; EPS, extrapyramidal symptoms; ML, most likely; SE, standard error;TD, tardive dyskinesia.
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Scenario Analyses
The NICE schizophrenia guidelines suggest the use
of atypical antipsychotics for the early treatment of
schizophrenia. This suggestion has been based on the
evidence that atypical antipsychotics cause fewer EPS.
In the base case of the model, three additional differ-
ences between atypicals and conventionals have been
included based on literature. These differences concern
a difference in compliance [66,67], in time between
relapses [26,39,42], and in PANSS reduction
[5,50,51]. To investigate the impact of these various
differences on the model’s results, four model runs
have been carried out in a stepwise procedure. In the
ﬁrst run, only the difference in side-effect proﬁles
between atypicals and conventionals is included. In
consecutive runs, in a stepwise manner the differences
in compliance, the time between relapses and in
PANSS reduction are included.
Results
The base-case estimates of costs and effectiveness
outcomes are summarized in Table 3. Starting with
atypicals rather than conventionals was predicted to
result in cost savings of £1633 (~3% of total costs).
Drug costs increase by £1258, while hospital costs
decrease by £2730. Hence, the reduction in hospital-
ization compensated for the higher cost of the atypi-
cal medications. It is expected that the atypicals on
average avoid 16 hospital days per patient over
5 years. Table 4 shows that compared to convention-
als, atypical drugs were predicted to reduce PANSS
scores, increase time on ﬁrst treatment, and improve
quality of life. Thus, conventional antipsychotic treat-
ment appeared to be dominated by atypicals because
the latter were associated with cost savings (of
£1633) and QALY gains (of 0.10). At a WTP of
£30,000 per QALY gained, the expected incremental
net beneﬁt (INB = DE*WTP - DC) of the atypical
treatment arm was £4668 per patient over a 5-year
period.
Average time on ﬁrst treatment was 1.36 years on
conventionals and 1.51 years on atypicals. After
5 years, about 70% of patients had experienced three
treatment switches and were on clozapine treatment.
Additionally the atypicals were expected to slightly
reduce the number of relapses suffered (by 0.03
relapses over 5 years). This reduction in the average
number of relapses realized by atypicals was smaller
than expected because of the comparatively high pro-
portion of patients on conventional depots in the UK
(and thus relatively high compliance).
The uncertainty surrounding the cost per QALY
gained is presented using a cost-effectiveness scatter
plot (Fig. 3a). The center of the cost-effectiveness
“cloud” lies below the x-axis, which indicates cost
savings, and to the right of the y-axis, which implies
health beneﬁts at the same time. The information con-
tained in the scatter plot is used to produce the accept-
ability curve (presented in Fig. 3b). This curve presents
Table 4 Overview of base-case cost and effect outcomes and incremental cost-effectiveness ratios for starting with a conventional
or with an atypical
Conventional
group
Atypical
group Difference
Discounted costs
(by cost component)
Community care
Intense community care
£4,282
£3,541
£4,349
£3,587
£67
£46
Staffed hostel £14,710 £14,462 -£248
Hospital £30,072 £27,343 -£2,730
Drug costs (incl. depot cost) £3,588 £4,846 £1,258
Psych visits £3,349 £3,322 -£27
Undiscounted costs
(over time)
Year 1
Year 2
£14,156
£11,376
£14,082
£11,135
-£75
-£241
Year 3 £12,893 £12,313 -£580
Year 4 £12,519 £12,097 -£422
Year 5 £12,858 £12,389 -£469
Total discounted £59,541 £57,908 -£1,633
QALY Discounted 5-year total 3.53 3.64 0.10
Percentage of time
spent per location
Community care
Intense community care
63.3%
13.1%
64.3%
13.3%
1.0%
0.2%
Staffed hostel 13.8% 13.6% -0.2%
Hospital 9.7% 8.8% -0.9%
Percentage of total
cost spent per location
Community care
Intense community care
7.2%
5.9%
7.5%
6.2%
0.3%
0.2%
Staffed Hostel 24.7% 25.0% 0.3%
Hospital 50.5% 47.2% -3.3%
Discontinuation of
ﬁrst treatment
Time on Tx1 (years)
% still on Tx1 after 1 year
1.36
66.5%
1.51
72.4%
0.15
5.9%
Relapses Number of relapses 2.67 2.64 -0.03
Total relapse time 2.31 2.27 -0.03
Average PANSS 5-year total 62.7 59.8 -2.9
PANSS, Positive and Negative Symptom Score; QALY, quality-adjusted life-year.
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the probability of the “experimental” treatment being
cost-effective compared to its comparator for various
WTP thresholds, which are presented on the x-axis.
In the UK, there is general consensus among policy-
makers that a WTP threshold for a QALY gained
of approximately £30,000 is acceptable [8]. At this
threshold, with the given levels of uncertainty, the
probability of atypicals being cost-effective compared
to conventionals is 98.2%.
In Table 5, all variables are presented, which in the
OLS analysis had a signiﬁcant impact (P-value < 0.05)
on incremental costs and/or effects that were generated
in the multivariate sensitivity analysis. These variables
have been sorted in descending order of their impact
on the incremental outcomes. The last three columns
of the table provide information about the inﬂuence of
the worst case values. The values of the worst case and
base-case values for a variable have been reproduced
in columns 4 and 5. The product of the difference
between these values multiplied by the regression
coefﬁcient is presented in column 6.
The results in Table 5 (part A) demonstrate that
incremental costs were sensitive to changes in the
values used of the parameters associated to whether
or not the patient was at risk. Differences in the risk
regression transformed the difference in PANSS
reduction between conventionals and atypicals into a
difference in hospitalization costs. Also, the difference
between conventionals and atypicals in terms of
PANSS reduction, compliance, and time between
relapses had a signiﬁcant impact on incremental
costs.
From Table 5 (part B), it can be concluded that
incremental effects are most sensitive to changes in the
parameters of the QALY–PANSS relationship and the
utility weights used in the calculations. The coefﬁcients
for EPS, tardive dyskinesia, and sedation were nega-
tive, because atypicals reduced these side effects, while
coefﬁcients hold for weight gain and diabetes, which
are side effects more common in patients on atypicals.
Side effects, especially those associated with serious
consequences for quality of life such as tardive
a
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Figure 3 (a) Scatter plot of incremental costs
and quality-adjusted life-years (QALYs) based
on a 1000 runs of 10,000 patients. The larger
portion of the scatter plot is found underneath
the £30,000/QALY threshold, suggesting that
treating patients with atypicals is likely to be
cost-effective at the National Institute for
Health and Clinical Excellence threshold of
£30,000/QALY. (b) Acceptability curves: the
probability that the new treatment option is
cost-effective given variousWTP thresholds for
a QALY gained.
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dyskinesia and diabetes, evidently had an important
inﬂuence on incremental effects. In terms of effect size,
the worst case value for the difference in PANSS reduc-
tion between atypicals and conventionals during epi-
sodes had the greatest impact on the incremental
QALYs.
Scenario Analyses
Table 6 presents the cumulative nature in which the
mechanisms which are made explicit in the model
affect incremental costs, effects, and the ICUR. The
more the model incorporates speciﬁc advantages of
atypicals, the higher the incremental effects of the
Table 5 Regression analysis of incremental costs and effects (QALY) based on 1000 runs
Variables Estimate P-value BC
Worst
case
New DC
BC = -£1633
A. Incremental costs regression
PANSS reduction on atypicals (relapse) 15,090 0.000 0.80 0.93 £435
PANSS-risk regression beta 0 -1,197 0.000 -5.131 -6.802 £368
PANSS-risk regression beta 1 -121,400 0.000 0.0403 0.0299 -£366
Days in hospital -35 0.000 40 13 -£668
Hospital location cost -0.04 0.000 63,350 42,391 -£887
Compliance rate between relapses community treatment atypical oral -3,361 0.000 0.65 0.43 -£907
PANSS episode partial recovery patients -125 0.000 47.0 42.5 -£1,067
Compliance rate during relapses community treatment atypical oral -2,153 0.000 0.60 0.40 -£1,210
PANSS reduction on atypicals (TBR) 4,371 0.000 0.95 1.044 -£1,220
Compliance rate between relapses community treatment conventional oral 2,104 0.000 0.60 0.79 -£1,235
Percentage partial recovery patients -2,324 0.000 0.62 0.45 -£1,236
Compliance rate during relapses community treatment conventional oral 1,562 0.000 0.55 0.72 -£1,375
Probability of switching because of somnolence 987 0.007 0.30 0.51 -£1,425
Percentage of nonsevere patients 710 0.041 0.10 0.33 -£1,468
Shortening of TBR because of noncompliance atypicals 412 0.001 3.70 4.05 -£1,489
Variables Estimate P-value BC
Worst
case
New DE
BC = 0.101
B. Incremental effects regression*
PANSS Reduction on atypicals (relapse) -0.306 0.000 0.80 0.93 0.059
QALY–PANSS regression beta -7.363 0.000 -0.0043 -0.0023 0.086
Utility score EPS -0.253 0.000 0.89 0.95 0.086
Incidence weight gain olanzapine -0.034 0.000 0.41 0.78 0.088
Utility score weight gain 0.390 0.000 0.96 0.93 0.089
Incidence EPS ﬂupentixol depot 0.028 0.000 0.58 0.17 0.089
Compliance rate between relapses community treatment atypical oral 0.051 0.000 0.65 0.43 0.090
PANSS reduction on atypicals (TBR) -0.109 0.000 0.95 1.04 0.091
Percentage partial recovery patients 0.056 0.000 0.62 0.45 0.091
Compliance rate during relapses community treatment atypical oral 0.048 0.000 0.60 0.40 0.092
Incidence somnolence olanzapine -0.030 0.000 0.30 0.59 0.092
Incidence somnolence quetiapine -0.020 0.000 0.55 0.93 0.093
Zuclophentixol depot EPS 0.020 0.000 0.58 0.19 0.093
Utility score somnolence -0.123 0.000 0.91 0.97 0.094
Incidence EPS haloperidol oral 0.017 0.000 0.58 0.14 0.094
Utility score TD -0.149 0.000 0.86 0.91 0.094
Incidence somnolence ﬂupentixol depot 0.020 0.000 0.49 0.14 0.094
Probability of switching after side-effect EPS -0.037 0.000 0.30 0.48 0.094
Incidence EPS olanzapine -0.043 0.000 0.16 0.30 0.095
Incidence EPS risperidone oral -0.026 0.000 0.27 0.49 0.095
Incidence somnolence risperidone oral -0.024 0.000 0.27 0.50 0.096
Incidence somnolence amisulpride -0.019 0.000 0.27 0.54 0.096
PANSS episode partial recovery patients 0.001 0.000 47 42 0.096
Probability of switching after side-effect somnolence -0.024 0.000 0.30 0.51 0.096
Incidence weight gain quetiapine -0.020 0.000 0.33 0.58 0.096
Compliance rate during relapses community treatment conventional oral -0.028 0.000 0.55 0.72 0.096
Incidence somnolence haloperidol oral 0.013 0.000 0.49 0.16 0.097
Incidence EPS triﬂuoperazine 0.010 0.000 0.58 0.14 0.097
Incidence TD ﬂupentixol depot 0.122 0.000 0.05 0.02 0.097
Incidence EPS amisulpride -0.012 0.000 0.33 0.65 0.097
Incidence EPS chlorpromazine 0.016 0.000 0.33 0.08 0.097
Incidence somnolence sulpiride 0.010 0.000 0.49 0.13 0.097
Incidence TD zuclophentixol depot 0.104 0.000 0.054 0.019 0.097
Compliance hospital atypical oral 0.011 0.000 0.80 0.45 0.097
*For the incremental effects OLS, a total of 67 parameters were found to be signiﬁcant, only 34 are shown here.The remaining 33 did not lower incremental effects by more
than 0.03 (i.e.,New DE0.098).Most of the parameters that were omitted deal with the incidence of side effects on the different treatments, and compliance rates in the different
locations.
BC, base case; EPS, extrapyramidal symptoms; PANSS, Positive and Negative Symptom Score; QALY, quality-adjusted life-year;TBR, time between relapses;TD, tardive dyskinesia.
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atypicals are and the lower incremental costs are.
When assuming, similar to the NICE recommenda-
tions, only differences in the side-effect proﬁles of both
types of antipsychotics, the ICUR is £45,205/QALY
gained.
Discussion
The aim of this study was to assess the cost-utility of
atypical antipsychotics in the treatment of schizophre-
nia compared to conventionals in the UK. On the basis
of our calculations, it can be concluded that starting
treatment of schizophrenia with an atypical instead of
a conventional is associated with cost savings and with
improved quality adjusted health over a 5-year period.
Sensitivity analyses have shown that this conclusion of
cost-effectiveness was quite robust to changes in input
variables. The probabilistic analyses showed that
atypicals will be cost-effective in a society where the
WTP for a QALY is £30,000.
Our model calculations provide support for the
NICE treatment guidelines which suggest that atypical
antipsychotics should be considered for the ﬁrst-line
treatment of schizophrenia [4]. This conﬁrmation is
not unequivocal. The argumentation behind the NICE
recommendation relied mainly on EPS being avoided
by atypicals compared to conventionals, while in the
base case the model included additional differences
that are believed to exist between the treatments. The
scenario analysis which reﬂects the NICE recommen-
dation, i.e., assumes only differences in side effects
between atypicals and conventionals, indicates that the
use of atypicals would be associated with an ICUR of
approximately £45,000/QALY. This ICUR decreases
dramatically if a difference in compliance, the time
between relapses and PANSS reduction, is also
assumed to a dominant ICUR in the last scenario,
which is also the base case.
The debate in the literature of the cost and effects
of atypicals and conventionals is inconclusive
[5,14,39,46–51,68–73]. For instance recently, Jones
et al. concluded that in people with schizophrenia
whose medication is changed for clinical reasons that
there is no disadvantage across 1 year in terms of
quality of life, symptoms, or associated costs of care in
using conventional antipsychotics rather than atypical
antipsychotics (nonclozapine) [69]. Moreover, in a
12-month study, Rosenheck et al. found that olanzap-
ine demonstrated no advantages over haloperidol (with
prophylactic benztropine against EPS) in compliance,
symptoms, EPS, and quality of life [74]. Furthermore,
Lewis et al. argue that conventional antipsychotic drugs
still have a place in the treatment of patients unrespon-
sive to, or intolerant of, current medication [75]. Kane
et al. and Mahmoud et al. however, found that clini-
cally relevant quality of life gains were more frequent
with an atypical than with a conventional antipsychotic
[70,71]. Further, Schooler et al. also showed that the
time between relapses is longer on risperidone than on
haloperidol [39]. The length of study, the choice of
(conventional) comparator (and potential concomitant
treatments), patient selection, dosing used, outcome
measures used, and the trial setup may explain this
variation in the evidence [5,74,76].
The version of the model used for the current article
was an upgrade of an earlier one [11–13]. This version
of the model is suitable to carry out second-order
Monte Carlo simulation and therefore has the capacity
to investigate uncertainty across populations rather
than across individuals. This is important because
reimbursement decisions have to be taken on the basis
of uncertainty around incremental cost-effectiveness
ratios at the population level. NICE guidelines [64]
indicate that such a probabilistic analysis is mandatory
for all applications to be evaluated by NICE.
As much as was feasible, data from the literature
have been used in the model calculations. Neverthe-
less, because of the lack of long-term data in schizo-
phrenia, it is still unavoidable to make a few
assumptions which have been substantiated by expert
opinion. Therefore, predicted costs per patient, treat-
ment location, and disease progression were compared
with published sources. The modeled PANSS scores
over time reﬂected the observations from Mahmoud
et al. [70] and from the ongoing University Medical
Center Utrecht cohort study at model entry and after 1
and 5 years, respectively. The average patient in the
model was in relapse for 27.7 months over 5 years,
which was 46% of the modeled 5 years. This is in line
with the ﬁndings from Mason et al. [77] and Lenoir
et al. [78]. Compared to that of Knapp et al., the prob-
ability in the model to be treated in a certain treatment
setting appeared to be modeled quite conservatively
with the average patient spending approximately 78%
of time in the community (of which 15% in intense
community care), 14% in a staffed hostel, and 8% in
hospital (in the conventional treatment arm) [79]. The
shift from hospital to community care reﬂects efforts
that have been made since Knapp’s publication to
reduce the number of long-term psychiatric inpatients.
Additionally, similar to Guest and Cookson, the total
annual (undiscounted) direct care costs in the model
were estimated at approximately £10,000 per patient
Table 6 Sensitivity analysis: Analysis of the inﬂuence of the
assumed differences between conventionals and atypicals
Included differences
Incremental
costs Effects ICUR
Side effects only £1,917 0.042 £45,205
+ Compliance £1,695 0.046 £36,699
+ Time between relapses £845 0.048 £17,778
+ PANSS reduction -1,633 0.101 Dominant
ICUR, incremental cost-utility ratio; PANSS, Positive and Negative Symptom Score.
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[80]. The model predicted that time on ﬁrst-line treat-
ment was about 15% longer for atypicals than for
conventionals. These differences were also found in a
large observational study [81], but not in CATIE [14].
Finally, with respect to the variables differing
between the conventionals and the atypicals, the indi-
vidual drugs within the group of atypicals and within
the group of conventionals were assumed to have an
identical effect. This was necessary because relevant
comparative studies between the different atypicals
were not available. A number of sources suggest that
some differences do exist between individual drugs.
Tiihonen et al., for example, found signiﬁcant differ-
ences in the incidence of relapses between different
atypical and conventional drugs in an observational
study, even when corrected for patient characteristics
[82]. Further research into any efﬁcacy differences that
might exist between individual drugs is needed to test
this assumption, which can then be incorporated into
the model together with more detailed drug-speciﬁc
cost-effectiveness estimates.
Conclusion
According to this DES model for schizophrenia, atypi-
cal antipsychotics are cost-effective compared to the
conventional antipsychotics. The assumptions used in
the model need further validation through large natu-
ralistic based studies with reasonable follow-up to
determine the real-life differences between atypicals
and conventional antipsychotics.
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Appendix A: Disability to Care Index
The treatment setting assigned to a patient depends on
the level of self-care ability. This level is operational-
ized using the disability to care index (DCI), which in
turn depends on the patient’s PANSS and social and
environmental factors (SEFs). The DCI ranges from 0
to 10 and patients are classiﬁed into three levels of
self-care ability (able to care, moderately able to care,
not able to care) according to prespeciﬁed DCI thresh-
olds. This classiﬁcation of a patient’s self-care ability
plays an important role in the treatment location deci-
sion made by the psychiatrist.
The formula used to calculate DCI is the following:
DCI
SEF PANSS
=
× + −( ) ×α α1
10
trans
Where a is the SEF weight, and PANSStrans is a
patient’s PANSS scores transformed from its usual
range (30–210) to a range from 0 to 100 using a
cumulative normal distribution. This shape was
chosen in order to ensure sensitivity over the relevant
PANSS range while still being able to deal with all
possible PANSS scores.
Figure 4 shows the relationship between PANSS
and DCI, and the inﬂuence of a. With an a of 0 (the
blue circles) only PANSS inﬂuences DCI. With an SEF
weight of 0 (the green diamonds), patients have an
average DCI of 5, independent of their PANSS score.
With an a> 0 SEFs have, on average, a diluting effect
on the inﬂuence of PANSS on the disability index and
thus location (e.g., the red diamonds, with an a of 0.5).
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Figure 4 Disability to care index (DCI) against Positive and Negative
Symptom Score (PANSS) for different a-weights.
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